NASDAQ:VXRTVaxart Stock Price, Forecast & News

Vaxart's stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VXRT shares have increased by 40.6% and is now trading at $2.91. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaxart.

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Vaxart.

Vaxart Inc (NASDAQ:VXRT) released its quarterly earnings data on Tuesday, May, 12th. The biotechnology company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.02. The biotechnology company had revenue of $2.90 million for the quarter, compared to analyst estimates of $2.80 million. Vaxart had a negative return on equity of 94.20% and a negative net margin of 252.86%. View Vaxart's earnings history.

Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

2 equities research analysts have issued twelve-month target prices for Vaxart's stock. Their forecasts range from $6.00 to $7.00. On average, they expect Vaxart's share price to reach $6.50 in the next year. This suggests a possible upside of 123.4% from the stock's current price. View analysts' price targets for Vaxart.

News coverage about VXRT stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vaxart earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutVaxart.

Some companies that are related to Vaxart include BioCryst Pharmaceuticals (BCRX), Proteon Therapeutics (PRTO), BAVARIAN NORDIC/S (BVNRY), Replimune Group (REPL), Adaptimmune Therapeutics (ADAP), Aerie Pharmaceuticals (AERI), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Vericel (VCEL), AVITA MED LTD/S (RCEL), Avrobio (AVRO), Prevail Therapeutics (PRVL), Oyster Point Pharma (OYST), Aptose Biosciences (APTO) and MeiraGTx (MGTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), VBI Vaccines (VBIV), Conatus Pharmaceuticals (CNAT), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Agile Therapeutics (AGRX) and Co-Diagnostics (CODX).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.73%), Hussman Strategic Advisors Inc. (0.71%), Geode Capital Management LLC (0.48%), Harvest Investment Services LLC (0.07%), Bank of New York Mellon Corp (0.06%) and Strategic Wealth Management Group LLC (0.02%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour. View institutional ownership trends for Vaxart.

VXRT stock was bought by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., BlackRock Inc., Geode Capital Management LLC, Harvest Investment Services LLC, Bank of New York Mellon Corp, and Strategic Wealth Management Group LLC. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour. View insider buying and selling activity for Vaxart.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VXRT stock can currently be purchased for approximately $2.91.

Vaxart has a market capitalization of $215.86 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 34 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 650-550-3500 or via email at [email protected]